Have you heard of the START (Strategic Timing of Antiretroviral Treatment) study? In my opinion, it is probably the most important study currently running. It generates strong views, both for and against initiating antiretroviral therapy early, but the results are likely to be surprising.
25 November 2014 | The Body
The media coverage of the unexpectedly early success of two trials of pre-exposure prophylaxis - PrEP - has generally been positive, sometimes overly so. But I haven't seen anything that actually explains why the results of the PROUD and IPERGAY studies are so important, or why they represent a gear-change in the accelerating race towards the end of HIV.
05 November 2014 | Huffington Post
A new clinical trial is exploring whether giving anti-HIV therapy soon after birth to infants who became infected with HIV in the womb leads to remission of the virus, enabling the children eventually to stop treatment for an extended time period. The trial aims to build on the case of the 'Mississippi Baby'.
05 November 2014 | National Institute of Allergy and Infectious Diseases (NIAID) press release
IRMA applauds the launch of the world’s first-ever Phase II rectal microbicide trial. The Microbicide Trial Network’s study, called MTN-017, will test a reduced glycerin formulation of tenofovir gel applied rectally. Volunteers consisting of gay men, other men who have sex with men, and transgender women will participate in the study at sites in the United States and in Thailand, South Africa, and Peru.
02 October 2014 | IRMA
An experimental single-tablet regimen containing a new version of tenofovir (tenofovir alafenamide or TAF) and the HIV protease inhibitor darunavir (Prezista) worked as well as a similar regimen containing the older tenofovir disoproxil fumarate (TDF) formulation,but it had less detrimental effects on kidney function and bone density, as study presented at the recent ICAAC conference heard.
09 September 2014 | HIVandhepatitis.com
Social/behavioral intervention vastly increased the number of African American and Latino individuals living with HIV/AIDS who enrolled in HIV/AIDS medical studies, a study has found. Nine out of 10 participants who were found eligible for studies decided to enroll, compared to zero participants among a control group.
08 July 2014 | Science Daily
Merck (MSD) today announced that the first patient has been enrolled in the company’s global Phase 3 clinical trial, ONCEMRK. ONCEMRK is assessing a once-daily investigational formulation of ISENTRESS® (raltegravir), known as reformulated raltegravir, as part of combination HIV therapy for treatment-naïve HIV-1-infected adults. Raltegravir combines high potency with low toxicity but its more widespread use has been held back by its needing to be taken twice a day.
06 June 2014 | Merck
The randomized controlled trial, or RCT, represents the gold standard of interventional studies of new drugs. But how reliable are the results when it remains unknown whether subjects in the trial actually took their medicines at all? A 2007 analysis found that only 33% of 192 papers describing RCTs of oral therapies for six chronic diseases disclosed adherence results.
13 May 2014 | Nature Medicine
The benefits of the iPrEX trial have been localized - most volunteers in Peru, Ecuador, Brazil, Thailand and South Africa no longer have access to the drug.
06 May 2014 | Poz
A Spanish HIV/AIDS researcher is facing a hefty fine for violating clinical trial regulations. Vicente Soriano, a well-known clinical researcher with hundreds of publications to his name, is liable for €210,000 for conducting a clinical trial without approval from the Spanish Agency for Medicines and Health Products, failing to obtain insurance for the trial, and informing participants he had his hospital's ethical approval when he did not.
31 January 2014 | Science